NICE Endorses Dupilumab for Eosinophilic COPD T...

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance re...
Accelerating FAST-EU Clinical Trials
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
Navigating Economic Resilience Through Life Sciences Investment
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Equity-Based Pricing: Enhancing Value in Primary Care through Socioeconomic C...